1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis: RSV Vaccines and Therapeutics

Competitor Analysis: RSV Vaccines and Therapeutics

  • June 2012
  • -
  • La Merie Publishing
  • -
  • 30 pages

Competitor Analysis: Respiratory Syncytial Virus (RSV) Vaccines and Therapeutics

The present Competitive Intelligence Report about RSV Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, small molecules and RNAi against infection with respiratory syncytial virus (RSV) as of June 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Respiratory syncytial virus (RSV) infection, which manifests primarily as bronchiolitis and/or viral pneumonia, is the leading cause of lower respiratory tract infection in infants and young children. In the US, RSV LRT infection develops annually in 4-5 million children, and more than 125,000 children are admitted per year for RSV-related illness. RSV disease is the no.1 cause of hospitalization in babies under a year of age in the US. While a monoclonal antibody is commercially available to help prevent RSV disease in infants and children at high risk for severe lung disease from RSV, a RSV vaccine still is not on the market. A number of RSV vaccine candidates have entered clinical development and further are to follow. Also, next generation antibodies against RSV with improved features are in the development pipeline as well as new therapies based on silencing RSV RNA or inhibiting key targets of the virus.
The report includes a compilation of currently active projects in development of vaccines, antibodies, small molecules and small interfering RNA (siRNA) targeting respiratory syncytial virus for prophylaxis and treatment of RSV infections. In addition, the report lists company-specific R&D pipelines of RSV Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on:
-Drug Codes,
-Target / Mechanism of Action,
-Class of Compound,
-Company,
-Product Category,
-Indication,
-R&D Stage and
-additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: RSV Vaccines and Therapeutics
 Index

-RSV Vaccines
-Antibody-Based RSV Therapeutics
-Other Biologics as RSV Therapeutics
-Small Molecule RSV Therapeutics
-Corporate RSV Vaccines and Therapeutics RandD Pipeline
-About La Merie

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025

OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025

  • $ 9 495
  • Industry report
  • June 2016
  • by Global Data

OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025 Summary The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Therapies for Rheumatoid Arthritis: Technologies and Global Markets

Therapies for Rheumatoid Arthritis: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • July 2016
  • by BCC Research

This BCC Research report determines the current status of the market for rheumatoid arthritis treatments, and assesses their growth potential over a five-year period from 2016 through 2020. Use this report ...


Download Unlimited Documents from Trusted Public Sources

Antidepressant and Therapy Market in the US

  • September 2016
    21 pages
  • Antidepressant  

    Therapy  

  • United States  

View report >

Anti-Infective Market in the UK

  • September 2016
    19 pages
  • Anti-Infective  

  • United Kingdom  

    Europe  

View report >

Therapy Market in Sweden

  • September 2016
    8 pages
  • Therapy  

    Hormone  

    Antidiabetics  

  • Sweden  

View report >

Related Market Segments :

Therapy
Vaccine

ref:plp2012

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.